SEC Form 4 · accession 0001209191-18-030253
Clearside Biomedical, Inc. · CLSD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gerald D. Cagle
Director
Period of report
May 11, 2018
Accepted (ET)
May 15, 2018 · 5:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001539029
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 11, 2018 | M | 45,454 | $0.40 | A | 68,895 | D | |
| Common StockF1 | holding | — | — | — | 14,064 | I | See Footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $0.40 | May 11, 2018 | M | 45,454 | D | — | Jun 16, 2023 | Common Stock | 45,454 | 0 | D |
Explanation of responses
- F1Cagle Business Interests, Ltd. is the record holder of these securities. The reporting person is the general partner of Cagle Business Interests, Ltd. and may be deemed to share voting and dispositive power over these securities. The reporting person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
- F2Fully vested.